192 related articles for article (PubMed ID: 26265164)
21. Treatment and disease outcomes of migrants from low- and middle-income countries in the Australian HIV Observational Database cohort.
Tilley DM; Griggs E; Hoy J; Wright ST; Woolley I; Burke M; O'Connor CC;
AIDS Care; 2015; 27(11):1410-7. PubMed ID: 26679270
[TBL] [Abstract][Full Text] [Related]
22. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
23. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database.
Petoumenos K; Ringland C;
HIV Med; 2005 May; 6(3):155-63. PubMed ID: 15876281
[TBL] [Abstract][Full Text] [Related]
24. A Decade of Combination Antiretroviral Treatment in Asia: The TREAT Asia HIV Observational Database Cohort.
AIDS Res Hum Retroviruses; 2016 Aug; 32(8):772-81. PubMed ID: 27030657
[TBL] [Abstract][Full Text] [Related]
25. Acute coronary syndromes in indigenous Australians: opportunities for improving outcomes across the continuum of care.
Brown A
Heart Lung Circ; 2010; 19(5-6):325-36. PubMed ID: 20363187
[TBL] [Abstract][Full Text] [Related]
26. The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: results from the Australian HIV observational database.
Petoumenos K;
J Clin Virol; 2003 Feb; 26(2):209-22. PubMed ID: 12600652
[TBL] [Abstract][Full Text] [Related]
27. HIV and AIDS in aboriginal and Torres Strait Islander Australians: 1992-1998. The National HIV Surveillance Committee.
Guthrie JA; Dore GJ; McDonald AM; Kaldor JM
Med J Aust; 2000 Mar; 172(6):266-9. PubMed ID: 10860091
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes of first-line antiretroviral therapy in Latin America: analysis from the LATINA retrospective cohort study.
Angriman F; Belloso WH; Sierra-Madero J; Sánchez J; Moreira RI; Kovalevski LO; Orellana LC; Cardoso SW; Crabtree-Ramirez B; La Rosa A; Losso MH
Int J STD AIDS; 2016 Feb; 27(2):118-26. PubMed ID: 25740759
[TBL] [Abstract][Full Text] [Related]
29. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study.
Jani IV; Sitoe NE; Alfai ER; Chongo PL; Quevedo JI; Rocha BM; Lehe JD; Peter TF
Lancet; 2011 Oct; 378(9802):1572-9. PubMed ID: 21951656
[TBL] [Abstract][Full Text] [Related]
30. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda.
Mills EJ; Bakanda C; Birungi J; Chan K; Ford N; Cooper CL; Nachega JB; Dybul M; Hogg RS
Ann Intern Med; 2011 Aug; 155(4):209-16. PubMed ID: 21768555
[TBL] [Abstract][Full Text] [Related]
31. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
32. Better Indigenous Risk stratification for Cardiac Health study (BIRCH) protocol: rationale and design of a cross-sectional and prospective cohort study to identify novel cardiovascular risk indicators in Aboriginal Australian and Torres Strait Islander adults.
Rémond MGW; Stewart S; Carrington MJ; Marwick TH; Kingwell BA; Meikle P; O'Brien D; Marshall NS; Maguire GP
BMC Cardiovasc Disord; 2017 Aug; 17(1):228. PubMed ID: 28835227
[TBL] [Abstract][Full Text] [Related]
33. Risk factors associated with incident sexually transmitted infections in HIV-positive patients in the Australian HIV Observational Database: a prospective cohort study.
Mulhall BP; Wright ST; De La Mata N; Allen D; Brown K; Dickson B; Grotowski M; Jackson E; Petoumenos K; Foster R; Read T; Russell D; Smith DJ; Templeton DJ; Fairley CK; Law MG
HIV Med; 2016 Sep; 17(8):623-30. PubMed ID: 27019207
[TBL] [Abstract][Full Text] [Related]
34. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
[TBL] [Abstract][Full Text] [Related]
35. Improvements in HIV treatment outcomes among indigenous and non-indigenous people who use illicit drugs in a Canadian setting.
Milloy MJ; King A; Kerr T; Adams E; Samji H; Guillemi S; Wood E; Montaner J
J Int AIDS Soc; 2016; 19(1):20617. PubMed ID: 27094914
[TBL] [Abstract][Full Text] [Related]
36. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
[TBL] [Abstract][Full Text] [Related]
37. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
38. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada.
Patterson S; Cescon A; Samji H; Chan K; Zhang W; Raboud J; Burchell AN; Cooper C; Klein MB; Rourke SB; Loutfy MR; Machouf N; Montaner JS; Tsoukas C; Hogg RS;
BMC Infect Dis; 2015 Jul; 15():274. PubMed ID: 26183704
[TBL] [Abstract][Full Text] [Related]
39. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
40. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.
Laurent C; Kouanfack C; Laborde-Balen G; Aghokeng AF; Mbougua JB; Boyer S; Carrieri MP; Mben JM; Dontsop M; Kazé S; Molinari N; Bourgeois A; Mpoudi-Ngolé E; Spire B; Koulla-Shiro S; Delaporte E;
Lancet Infect Dis; 2011 Nov; 11(11):825-33. PubMed ID: 21831714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
